
    
      A Multicenter, Prospective, Randomized, Open-label, Phase 4 Trial Designed to Evaluate the
      Efficacy of the Timing of the Administration of a Telmisartan/S-Amlodipine(TelminuvoÂ®Tab.
      40/2.5mg) on 24-hour BP Control in Hypertensive Patients Inadequately Controlled by
      Telmisartan Monotherapy
    
  